LINCOCIN

This brand name is authorized in Australia, Ecuador, Japan, Lithuania, Mexico, Poland, Singapore, Spain, Turkey.

Active ingredients

The drug LINCOCIN contains one active pharmaceutical ingredient (API):

1	Lincomycin UNII M6T05Z2B68 - LINCOMYCIN HYDROCHLORIDE
	Lincomycin is an antibiotic produced by fermentation of Streptomyces lincolnensis. Lincomycin inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome.
	Read more about Lincomycin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LINCOCIN Solution for injection	MPI, EU: SmPC	Pharmaceutical Benefits Scheme (AU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01FF02	Lincomycin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01F Macrolides, lincosamides and streptogramins → J01FF Lincosamides
Discover more medicines within J01FF02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2530E, 5144R
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	28675-12-08, 3092-MEE-1117
ES	Centro de información online de medicamentos de la AEMPS	41290, 41468
JP	医薬品医療機器総合機構	6112003M1030, 6112400A2030, 6112400A4075, 6112400A6086, 6112400A7031
LT	Valstybinė vaistų kontrolės tarnyba	1006093, 1010486
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	62014, 62016, 65768
PL	Rejestru Produktów Leczniczych	100033597, 100037684
SG	Health Sciences Authority	01716P
TR	İlaç ve Tıbbi Cihaz Kurumu	8681308751027